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following the publication of the FOCUS trial (p < 0.001). Transfusion rates among 
patients with a minimum hemoglobin value of < 8 g/dL, a concurrent control group, 
were unchanged. Hospital-level variation in transfusion rates declined signifi-
cantly. CONCLUSIONS: The FOCUS trial had a major impact on practice patterns. 
Consistent with the theory that practice variation is due to clinical uncertainty 
about the benefits from alternative approaches to treatment, publication of the 
trial reduced provider-level variation. The policy implication is that the govern-
ment should fund trials of services thought to be ineffective because physicians 
respond to high-quality evidence. In most cases, the expected savings are large 
in relation to the trial costs.
respiratory-related disorders - CliniCal outComes studies
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ObjeCtIveS: Transfusion-Related Acute Lung Injury (TRALI) is a serious transfu-
sion complication resulting in pulmonary edema and respiratory failure. The study 
objectives were to assess TRALI occurrence and potential risk factors among inpa-
tient Medicaid beneficiaries under 65 years of age, during 2007-2010. MethOdS: This 
retrospective claims-based study utilized large Medicaid databases. Transfusions 
were identified by recorded procedure and revenue center codes, while TRALI was 
ascertained via ICD-9-CM diagnosis code. Revenue center units were used to quan-
tify blood use. Study evaluated TRALI rates (per 100,000 transfusion stays) among 
Medicaid beneficiaries, overall and by year, age, sex, race, number of units and 
blood components transfused. ReSULtS: Of 1,123,113 inpatient transfusion stays 
for Medicaid beneficiaries during 2007-2010, 162 had TRALI diagnosis recorded, an 
overall rate of 14.42 per 100,000 stays. Annual TRALI rates were 12.70, 10.67, 16.60, 
and 18.14, respectively. TRALI rates for ages 0-9, 10-19, 20-29, 30-39, 40-49, 50-59, 
and 60-64 were 5.15, 13.41, 17.22, 19.59, 19.44, 13.66, and 10.54. Rates for females 
and males were 12.78 and 17.28, whereas for whites and non-whites were 15.55 
and 13.45. TRALI rates by number of units were: 9.56 for 1 unit, 7.72 for 2-4 units, 
17.70 for 5-9 units, and 62.12 for > 9 units. Rates by blood component groups were: 
13.86 for RBCs only, 4.93 for plasma only, 23.22 for platelets only, 37.37 for platelets 
and plasma, 56.02 for RBCs and plasma, 43.12 for RBCs and platelets, and 74.75 for 
RBCs, plasma, and platelets. CONCLUSIONS: This is the first and largest-to-date 
claims-based TRALI study among Medicaid beneficiaries. The results show a possible 
trend of increasing TRALI occurrence over time. The findings also suggest that TRALI 
rates vary by age, sex, race, number of units, and blood components transfused, with 
highest rates for stays with > 9 units transfused and for stays with RBCs transfused 
in combination with plasma and platelets.
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ObjeCtIveS: Chronic obstructive pulmonary disease (COPD) is one of the lead-
ing causes of morbidity and mortality worldwide. Long-acting bronchodilators 
(LABs) are the mainstay of pharmacological maintenance therapy for COPD. 
However, the possibility that use of LABs may lead to risk of cardiovascular 
events remains debated. The objective is to provide a critical review of meth-
odologies employed to evaluate risk of cardiovascular events in patients with 
COPD using LABs. MethOdS: A targeted search was conducted in PubMed to 
identify all original published research reporting adverse cardiovascular events 
from clinical trials and observational studies. The search was limited to English 
language, but not restricted by publication date. Selected abstracts were reviewed 
for study population, treatment, follow-up duration, study design, and cardiovas-
cular events. ReSULtS: The search returned 131 citations, of which 19 reported 
results from original research. Among them, 10 studies (53%) were clinical trials 
and 9 (47%) were observational studies. For the clinical trials, sample sizes ranged 
from 204 to 6,184 patients; follow-up duration was 14 days to 4 years. For the 
observational studies, 6 (67%) were nested case-control studies, 2 (22%) cohort 
studies, 1 (11%) self-controlled case series study; sample sizes ranged from 1,043 to 
352,631 patients; follow-up duration was 52 weeks to 13 years. The most frequently 
reported cardiovascular events included arrhythmias, stroke, angina, myocardial 
infarction and cardiovascular death. While none of the clinical trials showed a 
statistically significant association between the use of LABs and increased risk of 
cardiovascular events, 5 observational studies did. CONCLUSIONS: The contro-
versy continues regarding the use of LABs and their cardiovascular safety. Short 
follow-up duration and exclusion of patients with previous history of cardiovas-
cular events are the main limitations to clinical trials, while observational studies 
may be limited by residual confounding by disease severity and immeasurable 
time bias. A well-designed observational study is warranted.
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and compared to those for the reference infliximab. ReSULtS: The current CDR 
SEB submission procedure represents a significant deviation from that for non-SEB 
products. The CDR Recommendation for the infliximab SEB included comments 
related to the clinical evidence demonstrating similar efficacy and safety to the 
reference infliximab. The indications recommended for reimbursement by the 
CDR are also consistent with those of Health Canada. We expect that infliximab 
SEB will undergo pan-Canadian Pharmaceutical Alliance negotiation, which would 
be followed by reimbursement decisions by the public plans. CONCLUSIONS: The 
first monoclonal antibody SEB received a positive CDR recommendation, in part, 
based on comparative clinical data demonstrating similar efficacy and safety. 
Non-monoclonal antibody SEBs lacking comparative phase III clinical studies have 
recently been approved by the European Medicines Agency. The CDR’s assessments 
of these products will be of great interest.
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ObjeCtIveS: The incremental impact of overweight/obesity on the chronic disease 
burden and health–related quality of life (HRQOL) among individuals with arthri-
tis is not fully understood. This study aimed to determine the additional influ-
ence of overweight/obesity on arthritis–attributable burden (joint limitation, work 
limitation, social activity limitation, and joint pain) and HRQOL (general health 
status, physical HRQOL, mental HRQOL, activity limitations) among a representa-
tive national sample of adults with arthritis in the United States (US). MethOdS: 
This study involved a cross–sectional, retrospective analyses of the 2013 Behavioral 
Risk Factor Surveillance System (BRFSS) data. The study sample included adults 
(≥ 18 years) with arthritis and related disorders. Based on their body mass index 
(BMI), participants were categorized into six groups: underweight, normal weight, 
overweight, and class I/II/III obese. Multivariable logistic regression models were 
fitted to assess the study objectives. Data analyses were conducted using SASv9.3 
(PROC SURVEY) procedures. ReSULtS: The study sample included 157,113 adults 
with arthritis, of which 138,707 (88.2%) were also overweight/obese. Class III obese 
adults with arthritis had higher odds of joint limitations (Odds ratio [OR] = 1.439), 
work limitations (OR = 1.144), social activity limitations (OR = 1.368), and joint pain 
(OR = 1.099) compared to normal weight adults. Class III obese adults also had 
greater odds of poor physical HRQOL (OR = 1.141), mental HRQOL (OR = 1.273), and 
activity limitations (OR = 1.233) in comparison to adults with normal weight. A simi-
lar pattern was observed when overweight/class I/II obese adults with arthritis were 
compared to normal weight adults with arthritis. CONCLUSIONS: Study results 
highlight a significant negative impact of overweight/obesity on arthritis–attribut-
able burden and HRQOL among individuals with arthritis. Weight management is 
critical towards improving HRQOL and alleviating the burden of arthritis. Providers 
should emphasize weight management during their interaction with adults with 
arthritis.
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ObjeCtIveS: The present study intended to investigate knowledge about osteo-
porosis among female students of university in Quetta., Pakistan. MethOdS: A 
Cross-sectional study was used to assessed the knowledge by a pre-validated self-
administered questionnaire containing 20 disease related questions. Convenience 
sampling technique was used for data collection. Descriptive analysis was used 
to demonstrate the characteristics of the study population. Inferential statistics 
(Mann-Whitney U test and Kruskal Wallis tests, p< 0.05) were used to assess 
the significance among study variables. ReSULtS: Out of 162 female students, 
153(81.5%) were single and were science faculty students 123 (75.9%) with the 
majority of the age group of less than 24 years. Mean age of the study partici-
pants was 21.91±1.74years. 134 (82.7%) have not been previously diagnosed of 
bone related problem or osteoporosis. The mean score of knowledge was 13.01±2.9 
(max 20). Department of study and living status were significantly associated with 
knowledge scores. CONCLUSIONS: The study concluded that females of science 
faculty and who had a better life style had better understanding of the disease, 
osteoporosis, but they need to know the availability of treatment for this disease 
in Pakistan and it is also necessary for them to know more about some specific 
risk factors.
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ObjeCtIveS: Clinical trials that find that widely-used treatments do not improve 
patient outcomes can reduce costs, but only if physicians modify their practice 
patterns accordingly. The FOCUS trial, which was published in the New England 
Journal of Medicine in late 2011, found that post-operative red blood cell trans-
fusions do not improve outcomes among patients undergoing surgery for hip 
fracture with hemoglobin levels over 8 g/dL. MethOdS: We studied transfusion 
trends in 6,437 patients who underwent surgery to repair a hip fracture between 
2009 and 2013 at 18 US community hospitals. The hospitals are unaffiliated but 
report data to the Institute for Health Metrics. The data include diagnosis and pro-
cedure codes, hemoglobin values, and red blood cell transfusions. ReSULtS: Age-, 
sex-, and comorbidity-adjusted transfusion rates among patients with a minimum 
post-operative hemoglobin value of 8 to 10 g/dL declined by 19 percentage points 
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ment option for a disease where few options existed. Based on studies reviewed, 
sildenafil and NAC treatments did not slow disease progression as measured by 
change in percent FVC and their use in IPF should be limited.
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ObjeCtIveS: Clinical trials of chronic obstructive pulmonary disease (COPD), a pro-
gressive disease with a substantial economic burden, primarily assess exacerbation 
rates based on health resource utilization (HRU), leading payers to focus on this 
endpoint as a cost driver. The drug approval process often requires documenta-
tion of clinically relevant improvements in measures such as forced expiratory 
volume in one second (FEV1); however, their link to longer-term outcomes, such as 
exacerbations and HRU are not known. We conducted a systematic review of the 
published literature to evaluate the linkage. MethOdS: We searched MEDLINE- and 
Embase-indexed English-language publications from 2002 through October 1, 2014 
for randomized controlled trials with ≥ 20 adult patients with COPD. Included trials 
described changes in FEV1or St. George’s Respiratory Questionnaire (SGRQ), as well 
as exacerbations or HRU. ReSULtS: We identified 13 trials among 1,196 publications 
reporting changes in SGRQ or FEV1 and rate of exacerbation and hospitalization. 
We combined FEV1 pre-bronchodilator values with FEV1trough values given the 
similarity of these variables. Based on the MCID value for SGRQ of 4 units, exacerba-
tions ranged from 0.414 to 5.61/person-year among those not reaching SGRQ MCID, 
compared with a range of 0.42-1.07/person-year among those reaching SGRQ MCID. 
Using a minimal clinically important difference (MCID) value for FEV1 of 100mL, the 
exacerbation rate ranged from 0.414 to 5.61/person-year among those not reaching 
FEV1 MCID, compared to 0.69 to 1.02/person-year among those reaching FEV1MCID. 
The annual hospitalization rate due to exacerbations ranged from 0.02-0.7/per-
son-year among those not reaching SGRQ MCID, and from 0.03-0.16/person-year 
among those reaching SGRQ MCID. Annual hospitalization rates due to exacerba-
tions ranged from 0.02-0.7/person-year among those not reaching FEV1 MCID, com-
pared to 0.05-0.16/person-year among those reaching FEV1MCID. CONCLUSIONS: 
Preliminary results suggest a relationship between clinically meaningful improve-
ments in bronchodilation and patient-reported outcomes and annualized exacerba-
tions and hospitalizations.
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ObjeCtIveS: To describe the use of heliox therapy in a case series of patients 
admitted to emergency department or/and intensive care unit of children hospital 
“Napoleon Franco Pareja” in Cartagena, Colombia. MethOdS: We described the 
clinical features and results of heliox therapy in a series of patients admitted in 
emergency room and/or intensive care unit. For qualitative variables proportions 
were used and for numeric variables were analyzed with averages and meas-
ures of dispersion. We compared the differences in categorical variables using 
the chi-square or Fisher exact test. The aplicative Epidat 3.1 was used for data 
analysis ReSULtS: Fifty two patients were included, of whom 59.6% were male. 
The mean age was 21.2 months (SD: 25.6). The two most frequent diagnoses were 
status asthmaticus (32.7%) and acute bronchiolitis (26.9%). Mortality was 5.8%. 
Success of heliox therapy was 76.9%. The route of administration was not related 
to the type of response. The duration of heliox therapy averaged 5.9 hours (SD 
4.1) in patients who did not respond favorably and 8.0 hours (SD 5.6) in those 
who responded to heliox. Fifty percent off patients did not need endotracheal 
intubation and all responded favorably to heliox therapy. CONCLUSIONS: A 
high success rate with heliox therapy was found in this case series. Its use is 
recommended as an adjunct therapy in the management of acute respiratory 
insufficiency.
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ObjeCtIveS: Disease modifying drugs are not yet available for the management 
of individuals with Chronic Obstructive Pulmonary Disease (COPD). Statin therapy, 
due to its anti-inflammatory properties is under consideration for the manage-
ment of COPD. This study examined the relationship between statin therapy and 
COPD-specific outcomes. MethOdS: Retrospective longitudinal dynamic cohort 
design using Medicaid claims data from multiple years (2005-2008) was utilized. 
Statin therapy was identified from the prescription drug file using the National 
Drug Codes (NDC). COPD-specific outcomes such as hospitalizations, emergency 
room and outpatient visits were identified based on a primary diagnosis of COPD. 
Multivariable logistic regressions with Inverse Probability Treatment Weights (IPTW) 
were used to examine the relationship between statin therapy and COPD-specific 
outcomes. The relationship between multimorbidity, statin medications and COPD-
specific outcomes was tested using an interaction term. Secondary analyses with 
ObjeCtIveS: Pneumonia-related 30-day readmission rates are publically reported 
as part of the Hospital Readmissions Reduction Program to improve quality of 
care for Medicare beneficiaries. We estimated the impact of pneumonia on inpa-
tient mortality and 30-day readmission rates in mechanically ventilated (MV) 
patients. MethOdS: We performed a cohort study of MV patients using the 
Premier Inpatient database (July 2012 to June 2013). Patients on MV for > = 1 day 
were included and classified based on those with a pneumonia-related diagno-
sis code and those without. Patients were followed for the entire period of their 
hospitalization. Inpatient mortality and rates of readmission for the thirty days 
post discharge were compared between the two groups using generalized linear 
models (GLMs). We estimated both outcomes using the binomial distribution, 
controlling for patient demographics, 3M™ All Patient Refined Diagnosis Related 
Group Severity and Mortality indices, and hospital characteristics. ReSULtS: A 
total of 65,246 patients met criteria, of which 15,421 (23.6%) carried a pneumonia 
diagnosis. Pneumonia patients were older (64.2 vs 58.0 years, p< 0.0001), more 
likely to be male (46.8% vs 45.3%, p= 0.0012), white (72.4% vs 66.9%, p< 0.0001), and 
on public insurance (75.6% vs 65.2%, p< 0.0001). Comparing outcomes, pneumo-
nia patients experienced significantly higher rates of mortality (25.5% vs. 18.1%, 
p< 0.0001) and 30-day readmission (15.3% vs. 12.9%, p< 0.0001). After adjustment 
for patient and institutional factors in the GLM regressions the risk of both out-
comes remained statistically significant with odds ratios of 1.05 (95% CI: 1.01 to 
1.10) for mortality and 1.11 (95% CI: 1.05 to 1.17) for 30-day readmission (p= 0.024 
and 0.0002, respectively). CONCLUSIONS: Pneumonia in MV patients increases the 
risk of mortality and 30-day readmissions. With penalties as high as 3% across all 
Medicare payments for readmission, efforts should continue to carefully evaluate 
the care of mechanically ventilated patients with pneumonia.
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ObjeCtIveS: Multimorbidity is highly prevalent among individuals with Chronic 
Obstructive Pulmonary Disease (COPD). The association between multimorbidity and 
COPD medication management is not well researched. This study sought to examine 
the association between multimorbidity and receipt of COPD medications among 
Medicaid beneficiaries with newly diagnosed COPD. MethOdS: Retrospective lon-
gitudinal dynamic cohort design was used and data were extracted from multiple 
years (2005-2008) of Medicaid Analytic eXtract (MAX) files. Medicaid beneficiaries with 
newly diagnosed COPD (N = 19,060) were identified using International Classification 
of Diseases Codes (ICD-9-CM) codes for COPD. ICD-9-CM codes for commonly co-
occurring conditions with COPD were used to create multimorbidity variable. These 
conditions included arthritis, cardiovascular diseases (CVD), depression, diabetes, 
hypertension, hyperlipidemia and osteoporosis. Medicaid beneficiaries with newly 
diagnosed COPD were categorized into following multimorbidity categories: 1) physi-
cal multimorbidity only; 2) mental multimorbidity only; 3) both physical and mental 
multimorbidity and 4) no multimorbidity. Receipt of COPD medications (short-act-
ing, long-acting bronchodilators and inhaled corticosteroids) was identified using 
National Drug Codes. Bivariate relationships between multimorbidity and COPD 
medication receipt were tested using chi-square test of independence. The associa-
tions between multimorbidity and COPD medication receipt were analyzed with logis-
tic and multinomial logistic regressions. ReSULtS: Among Medicaid beneficiaries 
with newly diagnosed COPD, 74.9% had at least one co-occurring chronic condition. 
After controlling for patient characteristics, adults with multimorbidity were less 
likely to receive COPD medications compared to those without any multimorbidity. 
For example those with physical multimorbidity were less likely to receive short-
acting bronchodilators (AOR: 0.82; 95% CI: 0.75, 0.89), long-acting bronchodilators 
(AOR: 0.86; 95% CI: 0.79, 0.93) and inhaled corticosteroids (AOR: 0.81; 95% CI: 0.75, 0.88) 
compared to those with no inflammation-related multimorbidity. CONCLUSIONS: 
Prevalence of multimorbidity is very high among Medicaid beneficiaries with newly 
diagnosed COPD. Our study findings suggest poor COPD medication management 
among those with multimorbidity.
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ObjeCtIveS: Idiopathic pulmonary fibrosis (IPF) is a rare, progressive form of 
fibrosing interstitial pneumonia which results in loss of lung function and pre-
mature mortality. The FDA first approved treatments for IPF in late 2014. The aim 
of this systematic review and network meta-analysis (NMA) is to perform a mixed 
treatment comparison of the efficacy of available pharmacologic treatments for 
IPF. MethOdS: Medline, EMBASE, CENTRAL, and PROSPERO were searched for ran-
domized clinical trials in patients with IPF and supplemented with hand searches. 
Only randomized trials consisting exclusively of IPF patients were included. All stud-
ies were independently abstracted by two analysts. The primary outcome of interest 
was the standardized mean difference between treatment and control of change in 
percent predicted forced vital capacity (FVC) from baseline to one year. ReSULtS: 
Literature review identified 1,191 records of which 36 met our inclusion criteria. 
Fixed effects pairwise comparisons of the standardized mean difference (SMD) of 
intervention versus placebo suggested better performance of nintendanib rela-
tive to other treatments with a 4.9% (95%CI: 3.8-6.0) standardized improvement 
relative to placebo in %FVC . This falls comfortably within the range of minimal 
clinically important difference for this endpoint as measured by other authors. 
The data structure for pirfenidone did not allow for comparison of %FVC. Sildenafil, 
N-acetylcysteine (NAC), and azathioprine did not show statistically significant 
improvement relative to placebo. CONCLUSIONS: Nintenadib offers a new treat-
